Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting
Cerenome reports early, encouraging safety and dosing data, but commercial impact remains distant.
What the company is saying
Cerenome is highlighting interim Phase 1 results from its ReSPECT-LM study of REYOBIQ in leptomeningeal metastases, emphasizing the absence of dose-limiting toxicities or discontinuations among the first 10 patients. The company frames the findings as evidence of feasibility and early tolerability for repeated dosing, supported by consistent dosimetry and preliminary tumor-cell reductions. The narrative stresses that no LM progression was seen at three and six months among evaluable patients, with only one progression at nine months. Executives, including COO Eric J. Daniels, M.D., and lead investigator Andrew J. Brenner, M.D., Ph.D., reinforce the message that these results support continued dose escalation and enrollment. The company also points to substantial non-dilutive funding, citing a $17.6 million CPRIT grant for ReSPECT-LM and a $3 million Department of Defense grant for pediatric brain cancer trials. While the tone is confident and forward-looking, Cerenome acknowledges the findings are preliminary, the study is ongoing, and regulatory approval has not been obtained.
What the data suggests
The interim data show that, among 10 patients, six received 13.2 mCi per administration and four received 26.4 mCi, with one patient receiving a cumulative 79.2 mCi—surpassing the prior single-dose maximum of 75 mCi. No dose-limiting toxicities or discontinuations occurred; the most common adverse events were nausea (60%), headache (40%), and decreased lymphocyte and white blood cell counts (each 40%). One patient experienced Grade 3 nausea, resolving within five days, and the only serious adverse event was unrelated to treatment. Radiation dosing was consistent across administrations, with a median 8% variation and a CSF effective half-life of 12%. The first patient at the highest dose received an estimated 207 Gy cumulative absorbed dose without toxicity; five patients at the lower dose received 85–137 Gy. No LM progression occurred at three or six months among evaluable patients (0/5 at each point), and only one of four had progression at nine months. Serial CSF monitoring showed tumor-cell reductions, with three patients reaching zero detectable cells, though one later relapsed. The study is funded by $17.6 million (CPRIT) and $3 million (DoD) grants, but no revenue, commercial milestones, or regulatory submissions are reported. The data are detailed for an early-phase trial but limited in scope and duration, with no efficacy claims beyond descriptive progression rates.
Analysis
The announcement presents interim Phase 1 clinical data with detailed safety and preliminary efficacy findings for REYOBIQ in leptomeningeal metastases, supported by specific patient-level and dosimetry data. However, the majority of forward-looking claims—such as targeting a Phase 2 study in 2027, defining recommended regimens, and creating long-term shareholder value—are aspirational and contingent on future enrollment, follow-up, and regulatory alignment. The benefits to shareholders are long-term and uncertain, as the product remains investigational with no regulatory approval or commercial pathway disclosed. While the $17.6 million grant funding is a positive signal for ongoing research, it does not translate into near-term earnings or commercial impact. The language around platform-building and precision oncology is promotional relative to the early-stage, small-sample data. No revenue, profit, or cash flow metrics are disclosed, capping the signal at weak_positive per the rules.
Risk flags
- ●The data are interim and based on a small cohort (10 patients), limiting statistical power and generalizability. Early safety and dosing consistency are positive, but efficacy signals remain preliminary and non-randomized.
- ●The product, REYOBIQ, is investigational and has not been approved by the FDA or any regulatory authority. Advancement to later-stage trials and eventual commercialization is uncertain and subject to regulatory hurdles.
- ●The timeline to value is long, with Phase 2 not expected until 2027. This exposes investors to extended development, clinical, and regulatory risk before any potential revenue or partnership opportunities.
- ●The company is reliant on grant funding ($17.6 million from CPRIT and $3 million from the Department of Defense) for its current studies. There is no disclosure of broader financial health, cash runway, or plans for future funding beyond these grants.
Bottom line
Cerenome's interim ReSPECT-LM data show encouraging early safety and dosing consistency for REYOBIQ in leptomeningeal metastases, with no dose-limiting toxicities and stable progression rates at three and six months among a small patient group. The company is well-supported by $17.6 million and $3 million in non-dilutive grants, reducing near-term funding risk for these trials. However, the findings are preliminary, non-randomized, and limited in patient numbers and follow-up duration, with no regulatory submissions or commercial milestones on the horizon. Advancement to Phase 2 is not expected until 2027, making any shareholder value realization a long-term prospect. Investors should focus on future updates regarding larger patient cohorts, randomized efficacy data, and regulatory progress as the key catalysts for a material re-rating. The most important takeaway is that while early safety is promising, the path to approval and commercial impact remains long and uncertain.
Announcement summary
(NASDAQ:CNSY) Cerenome, Inc. announced interim data from its ongoing ReSPECT-LM study of repeated intraventricular dosing of REYOBIQ™ (rhenium Re186 obisbemeda) in patients with leptomeningeal metastases (LM). The interim data were presented as a poster on November 13, 2026, at the Society for Neuro-Oncology (SNO) 31st Annual Meeting and Education Day. The poster reports on treatment exposure, safety, dosimetry, LM progression status, and cerebrospinal fluid (CSF) tumor-cell findings for the first 10 patients treated. No dose-limiting toxicities or adverse events leading to treatment discontinuation have been reported. One patient received three 26.4 mCi doses, totaling 79.2 mCi, which exceeds the highest single administration in the prior single-dose ReSPECT-LM study (75 mCi). Imaging showed the radiation dose delivered to the LM compartment was consistent from one treatment to the next within each patient, with a median variation of 8%. Dose escalation is ongoing. No LM progression was documented by the three- and six-month landmarks among evaluable patients (0/5 at each landmark), and progression was documented in 1 of 4 evaluable patients by nine months. Of the 10 patients, six received 13.2 mCi per administration and four received 26.4 mCi per administration. Primary cancers included melanoma (4), breast cancer (3), non-small cell lung cancer (1), ovarian cancer (1), and neuroendocrine cancer (1). Nine patients had received prior LM therapy, and three were receiving concurrent systemic treatment. All 10 patients had at least one treatment-emergent adverse event; the most common were nausea (60%), headache (40%), decreased lymphocyte count (40%), and decreased white blood cell count (40%). One patient had Grade 3 treatment-related nausea, which resolved within five days. The only serious adverse event, shortness of breath in a single subject, was considered unrelated to treatment. Serial monitoring with Cerenome’s CNSide® documented tumor-cell reductions in individual patients; three patients with detectable tumor cells at baseline later had samples with zero tumor cells/mL, with two remaining at zero at 9.2 and 2.3 months after the first dose, respectively. The first patient to complete three administrations at 26.4 mCi per dose received an estimated cumulative LM compartment absorbed dose of 207 Gy, with no dose-limiting toxicities. Five patients completing three administrations at 13.2 mCi per dose received cumulative LM compartment absorbed doses of 85–137 Gy. In patients who received repeat administrations, the absorbed dose per mCi varied little from dose to dose (median within-patient coefficient of variation, 8%), and the CSF effective half-life was 12%. The median blood-derived marrow absorbed dose was 0.023 Gy per administration (range, 0.010–0.41 Gy). The ReSPECT-LM study (NCT07098806) is an open-label, multicenter Phase 1 study evaluating three dose levels (13.2, 26.4, and 44.1 mCi) and three dosing intervals (every 14, 28, or 56 days) across eight planned cohorts, with three administrations per participant. REYOBIQ is investigational and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority for any use. ReSPECT-LM is funded by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT). The ReSPECT-PBC clinical trial for pediatric brain cancer is supported by a $3 million grant from the U.S. Department of Defense's Peer Reviewed Cancer Research Program. Eric J. Daniels, M.D., is Cerenome’s Chief Operating Officer. Andrew J. Brenner, M.D., Ph.D., Professor of Medicine at Mays Cancer Center at UT Health San Antonio, is the lead author of the poster.
Disagree with this article?
Ctrl + Enter to submit